WO2006014726A3 - Immunoglobulins comprising predominantly a man5glcnac2 glycoform - Google Patents

Immunoglobulins comprising predominantly a man5glcnac2 glycoform Download PDF

Info

Publication number
WO2006014726A3
WO2006014726A3 PCT/US2005/025731 US2005025731W WO2006014726A3 WO 2006014726 A3 WO2006014726 A3 WO 2006014726A3 US 2005025731 W US2005025731 W US 2005025731W WO 2006014726 A3 WO2006014726 A3 WO 2006014726A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycoform
immunoglobulins
predominantly
relates
present
Prior art date
Application number
PCT/US2005/025731
Other languages
French (fr)
Other versions
WO2006014726A2 (en
Inventor
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Original Assignee
Glycofi Inc
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycofi Inc, Tillman U Gerngross, Huijuan Li, Stefan Wildt filed Critical Glycofi Inc
Priority to CA002573554A priority Critical patent/CA2573554A1/en
Priority to AU2005269713A priority patent/AU2005269713A1/en
Priority to JP2007522696A priority patent/JP2008507535A/en
Priority to EP05790364A priority patent/EP1771478A2/en
Publication of WO2006014726A2 publication Critical patent/WO2006014726A2/en
Publication of WO2006014726A3 publication Critical patent/WO2006014726A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Abstract

The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Man5GlcNAc2.
PCT/US2005/025731 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a man5glcnac2 glycoform WO2006014726A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002573554A CA2573554A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a man5glcnac2 glycoform
AU2005269713A AU2005269713A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a Man5GlcNac2 glycoform
JP2007522696A JP2008507535A (en) 2004-07-21 2005-07-19 Immunoglobulin mainly containing MAN5GLCNAC2 glycoform
EP05790364A EP1771478A2 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a man5glcnac2 glycoform

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58992604P 2004-07-21 2004-07-21
US58997904P 2004-07-21 2004-07-21
US60/589,926 2004-07-21
US60/589,979 2004-07-21

Publications (2)

Publication Number Publication Date
WO2006014726A2 WO2006014726A2 (en) 2006-02-09
WO2006014726A3 true WO2006014726A3 (en) 2006-07-20

Family

ID=35506030

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025731 WO2006014726A2 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a man5glcnac2 glycoform

Country Status (5)

Country Link
EP (1) EP1771478A2 (en)
JP (1) JP2008507535A (en)
AU (1) AU2005269713A1 (en)
CA (1) CA2573554A1 (en)
WO (1) WO2006014726A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002926A1 (en) 2006-10-12 2008-05-16 Genentech Inc ALFA ANTILINPHOTOXINE ANTIBODY (LT-ALFA); COMPOSITION WITH THE ANTIBODY; PTA-7538 HYBRIDOMA; NUCLEIC ACID CODIFYING THE ANTIBODY; VECTOR AND CELL GUEST UNDERSTANDING NUCLEIC ACID; METHOD FOR INHIBITING THE ACTIVATED CELL PROLIFERATION P
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1211310A1 (en) * 1999-08-19 2002-06-05 Kirin Beer Kabushiki Kaisha Novel yeast variants and process for producing glycoprotein containing mammalian type sugar chain
WO2004074499A2 (en) * 2003-02-20 2004-09-02 Gerngross Tillman U Combinatorial dna library for producing modified n-glycans in lower eukaryotes
EP1505149A1 (en) * 2002-04-26 2005-02-09 Kirin Beer Kabushiki Kaisha Methylotroph producing mammalian type sugar chain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1211310A1 (en) * 1999-08-19 2002-06-05 Kirin Beer Kabushiki Kaisha Novel yeast variants and process for producing glycoprotein containing mammalian type sugar chain
EP1505149A1 (en) * 2002-04-26 2005-02-09 Kirin Beer Kabushiki Kaisha Methylotroph producing mammalian type sugar chain
WO2004074499A2 (en) * 2003-02-20 2004-09-02 Gerngross Tillman U Combinatorial dna library for producing modified n-glycans in lower eukaryotes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIBA YASUNORI ET AL: "Production of human compatible high mannose-type (Man5GlcNAc2) sugar chains in Saccharomyces cerevisiae", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 273, no. 41, 9 October 1998 (1998-10-09), pages 26298 - 26304, XP002202331, ISSN: 0021-9258 *
CHOI B-K ET AL: "Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 9, 29 April 2003 (2003-04-29), pages 5022 - 5027, XP002267831, ISSN: 0027-8424 *
SHINKAWA T ET AL: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 5, 31 January 2003 (2003-01-31), pages 3466 - 3473, XP002965857, ISSN: 0021-9258 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8883483B2 (en) 2000-06-28 2014-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Also Published As

Publication number Publication date
CA2573554A1 (en) 2006-02-09
EP1771478A2 (en) 2007-04-11
JP2008507535A (en) 2008-03-13
AU2005269713A1 (en) 2006-02-09
WO2006014726A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2006071856A3 (en) Immunoglobulins comprising predominantly a man5glcnac2 glycoform
WO2006014683A3 (en) Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform
WO2006066568A3 (en) Antibody
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2007147122A3 (en) Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
WO2008091954A3 (en) Optimized cd40 antibodies and methods of using the same
WO2007057773A3 (en) Photoactive compounds
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2007008583A3 (en) Improved protein expression comparison assay results and applications
WO2006020114A3 (en) Variant fc regions
IL184152A (en) Monoclonal antibodies against nkg2a, compositions comprising the same, uses thereof for the manufacture of medicaments, methods for their production and methods employing said antibodies
WO2007050569A3 (en) Polypeptide multilayer films and methods
WO2005047545A3 (en) Microarray controls
MY150621A (en) Anti-epha2 antibody
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
WO2006119056A3 (en) Lighter than air supersonic vehicle
WO2007049152A3 (en) Methods of producing stable b-lymphocytes
WO2006014726A3 (en) Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP1344827A3 (en) Antifreeze proteins from basidiomycetes
WO2008030564A3 (en) Aglycosylated antibodies and methods of making and using those antibodies
WO2004075021A3 (en) Molecular modeling methods
FR2855557B1 (en) TUYERE COMPONENT WITH INCREASED LIFETIME FOR AIRCRAFT TURBOMOTORS.
WO2005035490A3 (en) PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS
NL1021490A1 (en) Process for the preparation of a fluoropolymer.
WO2007036501A3 (en) Graft copolymer and use of the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2573554

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005790364

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007522696

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005269713

Country of ref document: AU

Ref document number: 200580024712.6

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1209/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005269713

Country of ref document: AU

Date of ref document: 20050719

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005269713

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005790364

Country of ref document: EP